The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Improving the long-term safety of CLL treatment
Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, comments on the main barriers to progressing treatment for patients with chronic lymphocytic leukemia (CLL). He mentions that advancements have been made in treatment efficacy, and long-term safety should now be focused on. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
